Jamie Kasuboski

Jamie is Vice President at OMX Ventures. Jamie previously focused on early-stage biotech investing and company creation while at RA Capital and served on the board of Enara bio, Avilar Therapeutics and Endor Therapeutics. Before joining RA, he was a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of both Tilos Therapeutics (acquired by Merck & Co.) and Rewind Therapeutics. He holds a B.S. in Biology with a minor in Chemistry from Hillsdale College and a Ph.D. in Molecular and Cellular Biology from the University of Notre Dame.